Lifeboat Foundation

Diagnosing schizophrenia as early as possible helps minimize the toll the neurological disorder takes on the body and the mind. Unfortunately the condition’s signs can be difficult to spot in the early stages.

That’s why researchers led by a team from the Indiana University School of Medicine have developed a test which offers a relatively simple and reliable way to check for current schizophrenia severity and future risk.

“Psychosis usually manifests in young adulthood – a prime period of life,” says neuroscientist Alexander Niculescu from the Indiana University School of Medicine. “Stress and drugs, including marijuana, are precipitating factors on a background of genetic vulnerability.”

Drug discovery is being transformed by advances in computational protein structure prediction and protein design.

Researchers from the University of Wisconsin-Madison (UW-Madison) have developed a novel approach for 3D printing functional human brain tissue.

The 3D printing process can create active neural networks in and between tissues that grow in a matter of weeks.

The researchers believe that their 3D bioprinted brain tissue provides an effective tool for modeling brain network activity under physiological and pathological conditions, and can also serve as a platform for drug testing.

Transposable elements are mobile genetic elements that can relocate within the genome and disrupt the normal function of genes, but are at the same time a source of evolutionary diversity. The lab of Tugce Aktas at the Max Planck Institute for Molecular Genetics has identified a novel pathway that keeps the activity of transposons in somatic cells in check after they have been transcribed.

Their findings have now been published in Nature. The work is a collaboration with the labs of Zachary D. Smith at the Yale Stem Cell Center, U.S., and Franz-Josef Müller from the Universitätsklinikum Schleswig-Holstein, Germany.

Over the course of evolution, the genomes of many organisms have become cluttered with ancient genetic remnants from evolution or parts of retroviruses that inserted their genetic code millions of years ago. Nearly half of the human genome consists of these transposable elements, or transposons.

CRISPR/Cas systems have undergone tremendous advancement in the past decade. These precise genome editing tools have applications ranging from transgenic crop development to gene therapy and beyond. And with their recent development of CRISPR-COPIES, researchers at the Center for Advanced Bioenergy and Bioproducts Innovation (CABBI) are further improving CRISPR’s versatility and ease of use.

“CRISPR-COPIES is a tool that can quickly identify appropriate chromosomal integration sites for genetic engineering in any organism,” said Huimin Zhao, CABBI Conversion Theme Leader and Steven L. Miller Chair of Chemical and Biomolecular Engineering (ChBE) at the University of Illinois. “It will accelerate our work in the metabolic engineering of non-model yeasts for cost-effective production of chemicals and biofuels.”

Gene editing has revolutionized scientists’ capabilities in understanding and manipulating genetic information. This form of genetic engineering allows researchers to introduce new traits into an organism, such as resistance to pests or the ability to produce a valuable biochemical.

In a study published in Nature Nanotechnology, scientists from Delft University of Technology present a new technique to identify proteins. Proteins carry out essential functions in our cells, while playing a crucial role in diseases like cancer and COVID-19 infection. The researchers identify proteins by reading out the fingerprint, and comparing the fingerprint to patterns from a database.

Using this new technology, the researchers can identify individual, intact, full-length proteins, preserving all its information. This can shed light on the mechanisms behind many different diseases and allows earlier diagnosis.

Scientists from medical tech company Fluicell have partnered with clinical R&D firm Cellectricon and the Swedish Karolinska Institutet university to 3D bioprint neural cells into complex patterns.

Using the microfluidic printheads featured on Fluicell’s Biopixlar platform, the researchers were able to accurately arrange rat brain cells within 3D structures, without damaging their viability. The resulting cerebral tissues could be used to model the progress of neurological diseases, or to test the efficacy of related drugs.

“We’ve been using Biopixlar to develop protocols for the printing of different neuronal cells types, and we are very pleased with its performance,” said Mattias Karlsson, CEO of Cellectricon. “This exciting technology has the potential to open completely new avenues for in-vitro modeling of a wide range of central and PNS-related diseases.”

It’s electric! A startup emerged from stealth this week with grand plans to pioneer a new form of neurotech dubbed “electric medicine.”

Elemind’s approach centers on artificial intelligence-powered algorithms that are trained to continuously analyze neurological activity collected by a noninvasive wearable device, then to deliver through the wearable bursts of neurostimulation that are uniquely tailored to those real-time brain wave readings.

Machine learning algorithms play important roles in medical imaging analysis but can be affected by biases in training data. Jones and colleagues discuss how causal reasoning can be used to better understand and tackle algorithmic bias in medical imaging analysis.